drugset / Trial / NCT01561456
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare effectiveness and safety of experimental anticancer medicine, AXL1717, and docetaxel in patients with squamous cell carcinoma or adenocarcinoma of the lung.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AXL1717 | Small molecule | 400 mg | Oral |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |